JOP20220071A1 - سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra - Google Patents
سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15RaInfo
- Publication number
- JOP20220071A1 JOP20220071A1 JOP/2022/0071A JOP20220071A JOP20220071A1 JO P20220071 A1 JOP20220071 A1 JO P20220071A1 JO P20220071 A JOP20220071 A JO P20220071A JO P20220071 A1 JOP20220071 A1 JO P20220071A1
- Authority
- JO
- Jordan
- Prior art keywords
- immunocytokine
- protein complex
- heterodimeric protein
- complex based
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بسيتوكين مناعي immunocytokine يشمل معقد بروتين دايمري غير متجانس heterodimeric protein complex على أساس إنترلوكين 15 interleukin 15 (IL-15)/مستقبل إنترلوكين 15 ألفا interleukin 15 receptor alpha (IL-15R?)، واستخدامه كعامل علاجي therapeutic agent، وتحديدًا كعامل لعلاج السرطان cancer ولعلاج مرض مناعة ذاتية autoimmune disease. يتعلق الاختراع الحالي أيضًا بسيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس إنترلوكين 15/مستقبل إنترلوكين 15 ألفا وجسم مضاد معدِل مناعي immunomodulatory antibody، واستخدامه كعامل علاجي، وتحديدًا كعامل لعلاج السرطان ومرض مناعة ذاتية.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019129569A RU2753282C2 (ru) | 2019-09-19 | 2019-09-19 | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
PCT/RU2020/050233 WO2021054867A1 (ru) | 2019-09-19 | 2020-09-20 | Иммуноцитокин, включающий гетеро димерный белковый комплекс на основе il-15 и il-15rα |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220071A1 true JOP20220071A1 (ar) | 2023-01-30 |
Family
ID=74873995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0071A JOP20220071A1 (ar) | 2019-09-19 | 2020-09-20 | سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230011234A1 (ar) |
EP (1) | EP4032539A4 (ar) |
JP (1) | JP2022549276A (ar) |
KR (1) | KR20220145323A (ar) |
CN (1) | CN115297885A (ar) |
AR (1) | AR120011A1 (ar) |
AU (1) | AU2020351560A1 (ar) |
BR (1) | BR112022005173A2 (ar) |
CA (1) | CA3151780A1 (ar) |
CO (1) | CO2022003156A2 (ar) |
JO (1) | JOP20220071A1 (ar) |
MA (1) | MA56286B1 (ar) |
MX (1) | MX2022003306A (ar) |
PE (1) | PE20220603A1 (ar) |
RU (1) | RU2753282C2 (ar) |
TW (1) | TW202124420A (ar) |
UY (1) | UY38889A (ar) |
WO (1) | WO2021054867A1 (ar) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7479383B2 (ja) | 2018-09-27 | 2024-05-08 | エクシリオ デベロップメント, インコーポレイテッド | マスクされたサイトカインポリペプチド |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
JP6251570B2 (ja) * | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体il−15可溶性融合分子並びにその製造及び使用方法 |
EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
EP4269441A3 (en) | 2013-08-08 | 2024-01-24 | Cytune Pharma | Il-15 and il-15ralpha sushi domain based on modulokines |
CA2935599A1 (en) * | 2014-01-08 | 2015-07-16 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-15 heterodimeric protein and uses thereof |
EP3673915A1 (en) * | 2014-06-30 | 2020-07-01 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
SI3235830T1 (sl) | 2014-12-19 | 2020-12-31 | Jiangsu Hengrui Medicine Co., Ltd. | Proteinski kompleks interlevkina 15 in njegove uporabe |
RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
PE20191034A1 (es) | 2016-10-14 | 2019-08-05 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1 |
CA3200275A1 (en) * | 2016-10-21 | 2018-04-26 | Nantcell, Inc. | Multimeric il-15-based molecules |
US11129883B2 (en) * | 2017-03-06 | 2021-09-28 | Altor BioScience, LLC. | IL-15-based fusions to IL-12 and IL-18 |
RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
EP3645122A1 (en) * | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
EP3675892A4 (en) * | 2017-07-03 | 2021-10-06 | Torque Therapeutics, Inc. | IMMUNOSTIMULATORY FUSION MOLECULES AND THEIR USES |
-
2019
- 2019-09-19 RU RU2019129569A patent/RU2753282C2/ru active
-
2020
- 2020-09-18 AR ARP200102607A patent/AR120011A1/es unknown
- 2020-09-20 MX MX2022003306A patent/MX2022003306A/es unknown
- 2020-09-20 AU AU2020351560A patent/AU2020351560A1/en active Pending
- 2020-09-20 MA MA56286A patent/MA56286B1/fr unknown
- 2020-09-20 US US17/761,838 patent/US20230011234A1/en active Pending
- 2020-09-20 JO JOP/2022/0071A patent/JOP20220071A1/ar unknown
- 2020-09-20 CA CA3151780A patent/CA3151780A1/en active Pending
- 2020-09-20 BR BR112022005173A patent/BR112022005173A2/pt unknown
- 2020-09-20 CN CN202080080165.8A patent/CN115297885A/zh active Pending
- 2020-09-20 EP EP20865705.6A patent/EP4032539A4/en active Pending
- 2020-09-20 PE PE2022000447A patent/PE20220603A1/es unknown
- 2020-09-20 KR KR1020227013100A patent/KR20220145323A/ko unknown
- 2020-09-20 WO PCT/RU2020/050233 patent/WO2021054867A1/ru active Application Filing
- 2020-09-20 JP JP2022518285A patent/JP2022549276A/ja active Pending
- 2020-09-21 TW TW109132634A patent/TW202124420A/zh unknown
- 2020-09-22 UY UY0001038889A patent/UY38889A/es unknown
-
2022
- 2022-03-18 CO CONC2022/0003156A patent/CO2022003156A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR120011A1 (es) | 2022-01-26 |
RU2019129569A (ru) | 2021-03-19 |
AU2020351560A1 (en) | 2022-11-24 |
TW202124420A (zh) | 2021-07-01 |
BR112022005173A2 (pt) | 2022-08-16 |
EP4032539A1 (en) | 2022-07-27 |
US20230011234A1 (en) | 2023-01-12 |
CN115297885A (zh) | 2022-11-04 |
WO2021054867A1 (ru) | 2021-03-25 |
KR20220145323A (ko) | 2022-10-28 |
CO2022003156A2 (es) | 2022-04-19 |
MA56286B1 (fr) | 2023-09-27 |
MA56286A1 (fr) | 2023-05-31 |
UY38889A (es) | 2021-04-30 |
PE20220603A1 (es) | 2022-04-25 |
MX2022003306A (es) | 2022-04-26 |
JP2022549276A (ja) | 2022-11-24 |
RU2019129569A3 (ar) | 2021-03-19 |
CA3151780A1 (en) | 2021-03-25 |
RU2753282C2 (ru) | 2021-08-12 |
EP4032539A4 (en) | 2023-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220071A1 (ar) | سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra | |
MX2020010458A (es) | Conjugados de camptotecina-peptido. | |
PH12020500241A1 (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
PH12019502621A1 (en) | Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer | |
MX2020013169A (es) | Conjugados de camptotecina. | |
SG11201907321TA (en) | Anti-gprc5d antibody and molecule comprising the antibody | |
MX2021000083A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
CA3010621A1 (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
MX2022005411A (es) | COMPUESTOS DE UNIÓN A IL-2RßYC. | |
TW200531679A (en) | Methods of modulating cytokine activity; related reagents | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
ZA202105285B (en) | Antibody against human il-4ra and use thereof | |
MX2022005547A (es) | Derivados terapeuticos de interleucina-22. | |
GEP20247585B (en) | Furoindazole derivatives | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
ZA202003320B (en) | Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies | |
WO2020180712A8 (en) | Anti-tnfr2 antibodies and uses thereof | |
MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
MX2021010254A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. |